LENZ Therapeutics Past Earnings Performance
Past criteria checks 0/6
LENZ Therapeutics's earnings have been declining at an average annual rate of -53.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 95.5% per year.
Key information
-53.4%
Earnings growth rate
-30.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -95.5% |
| Return on equity | -28.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How LENZ Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -61 | 25 | 43 |
| 30 Jun 24 | 0 | -69 | 21 | 54 |
| 31 Mar 24 | 0 | -74 | 16 | 60 |
| 31 Dec 23 | 0 | -70 | 13 | 60 |
| 30 Sep 23 | 0 | -56 | 9 | 48 |
| 31 Dec 22 | 15 | -11 | 4 | 21 |
Quality Earnings: LENZ is currently unprofitable.
Growing Profit Margin: LENZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LENZ's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LENZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LENZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LENZ has a negative Return on Equity (-28.25%), as it is currently unprofitable.